FF Pharma is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibody production or chronic inflammation, are a feature. FF Pharma’s anti-CD40 antibody is a negative allosteric modulator of the CD40 pathway. It functions as a reversible switch for B cell activation and inhibits immune responses more “upstream” than for example cytokine inhibitors like TNF and IL-23 blockers. FF Pharma’s anti-CD40 antibody, if approved, would be a first in class molecule with a novel mechanism of action in treating inflammatory conditions.

Science and medicine

CD40 is a major regulatory receptor in the immune system. There is a wealth of literature supporting the involvement of the CD40 pathway in the pathophysiology of a variety of chronic inflammatory / autoimmune diseases.

FFP104, a monoclonal antibody targeting the CD40 molecule, interferes with (immunological) effects that are normally the consequence of CD40 activation. Fast Forward Pharmaceuticals is developing FFP104 for the treatment of Crohn’s Disease and Primary Biliary Cirrhosis.


R&D Program

FFP’s clinical focus is on the development of FFP104, an anti-CD40 monoclonal antibody, that we believe has the capacity to interfere with pathogenic disease processes in many inflammatory conditions.

Currently, a clinical study in healthy volunteers on the safety and tolerability of single and multiple doses of FFP104 is being completed. Our first targeted disease indication is Primary Biliary Cirrhosis, an orphan disease with a clear unmet medical need. In addition, FFP will develop FFP104 for the treatment of Crohn’s Disease.


FF Pharma company profile

FF Pharma is a privately owned biopharmaceutical company, which was founded in October 2012. The company’s lead product, FFP104 is a clinical stage deimmunized anti-CD40 monoclonal antibody.

FF Pharma has exclusively licensed from PanGenetics BV all of the underlying IP to allow development and commercialisation of FFP104 (formerly called PG102). FF Pharma has its headquarters in Utrecht, the Netherlands, and has set up a subsidiary at BioVille, the life sciences incubator in Diepenbeek, Belgium, to coordinate its development activities.